AI assistant
VERTEX PHARMACEUTICALS INC / MA — Director's Dealing 2021
Feb 26, 2021
29864_dirs_2021-02-26_eacaf430-561f-4810-9e3f-acd9bc57b42c.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK: 0000875320
Period of Report: 2021-02-24
Reporting Person: Parini Michael (EVP, Chief Adm, Leg & BD Off)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-02-24 | Common Stock | F | 2416 | $217.57 | Disposed | 33865 | Direct |
| 2021-02-25 | Common Stock | S | 646 | $211.58 | Disposed | 33219 | Direct |
| 2021-02-25 | Common Stock | S | 1348 | $213.04 | Disposed | 31871 | Direct |
| 2021-02-25 | Common Stock | S | 680 | $214.28 | Disposed | 31191 | Direct |
| 2021-02-25 | Common Stock | S | 354 | $216.26 | Disposed | 30837 | Direct |
Footnotes
F1: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1.
F2: Open market sales reported on this line occurred at a weighted average price of $211.58 (range $211.34 to $211.91).
F3: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F4: Open market sales reported on this line occurred at a weighted average price of $213.04 (range $212.76 to $213.68).
F5: Open market sales reported on this line occurred at a weighted average price of $214.28 (range $213.90 to $214.69).
F6: Open market sales reported on this line occurred at a weighted average price of $216.26 (range $215.79 to $216.76).